DK0666861T3 - Rapamycin-arylcarbonyl- og alkoxycarbonyl-carbamater som immunsuppressive og antifungiske midler - Google Patents
Rapamycin-arylcarbonyl- og alkoxycarbonyl-carbamater som immunsuppressive og antifungiske midlerInfo
- Publication number
- DK0666861T3 DK0666861T3 DK93923284T DK93923284T DK0666861T3 DK 0666861 T3 DK0666861 T3 DK 0666861T3 DK 93923284 T DK93923284 T DK 93923284T DK 93923284 T DK93923284 T DK 93923284T DK 0666861 T3 DK0666861 T3 DK 0666861T3
- Authority
- DK
- Denmark
- Prior art keywords
- arylcarbonyl
- rapamycin
- immunosuppressive
- image
- antifungal agents
- Prior art date
Links
- 229940121375 antifungal agent Drugs 0.000 title abstract 2
- 230000001506 immunosuppresive effect Effects 0.000 title abstract 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002930 sirolimus Drugs 0.000 title abstract 2
- -1 alkoxycarbonyl carbamates Chemical class 0.000 title 1
- 239000003429 antifungal agent Substances 0.000 title 1
- 229940125721 immunosuppressive agent Drugs 0.000 title 1
- 239000003018 immunosuppressive agent Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 206010017533 Fungal infection Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000031888 Mycoses Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000000843 anti-fungal effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/968,115 US5262423A (en) | 1992-10-29 | 1992-10-29 | Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents |
| PCT/US1993/009552 WO1994010176A1 (en) | 1992-10-29 | 1993-10-06 | Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0666861T3 true DK0666861T3 (da) | 1998-11-09 |
Family
ID=25513757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK93923284T DK0666861T3 (da) | 1992-10-29 | 1993-10-06 | Rapamycin-arylcarbonyl- og alkoxycarbonyl-carbamater som immunsuppressive og antifungiske midler |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5262423A (da) |
| EP (1) | EP0666861B1 (da) |
| JP (1) | JPH08502748A (da) |
| AT (1) | ATE166653T1 (da) |
| AU (1) | AU5322294A (da) |
| CA (1) | CA2148247A1 (da) |
| DE (1) | DE69318846T2 (da) |
| DK (1) | DK0666861T3 (da) |
| ES (1) | ES2116471T3 (da) |
| MX (1) | MX9306730A (da) |
| TW (1) | TW239136B (da) |
| WO (1) | WO1994010176A1 (da) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5480988A (en) * | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5480989A (en) * | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5434260A (en) * | 1992-10-13 | 1995-07-18 | American Home Products Corporation | Carbamates of rapamycin |
| US5489680A (en) * | 1992-10-13 | 1996-02-06 | American Home Products Corporation | Carbamates of rapamycin |
| US5349060A (en) * | 1993-01-07 | 1994-09-20 | American Home Products Corporation | Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents |
| US20020099067A1 (en) * | 1993-07-08 | 2002-07-25 | Ulrich Posanski | Pharmaceutical compositions for sparingly soluble therapeutic agents |
| CA2175215C (en) * | 1993-11-19 | 2008-06-03 | Yat Sun Or | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| US5527907A (en) * | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
| US5912253A (en) * | 1993-12-17 | 1999-06-15 | Novartis Ag | Rapamycin derivatives |
| US5525610A (en) * | 1994-03-31 | 1996-06-11 | American Home Products Corporation | 42-Epi-rapamycin and pharmaceutical compositions thereof |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| US5463048A (en) * | 1994-06-14 | 1995-10-31 | American Home Products Corporation | Rapamycin amidino carbamates |
| ES2187660T3 (es) | 1995-06-09 | 2003-06-16 | Novartis Ag | Derivados de rapamicina. |
| US6331547B1 (en) | 1999-08-18 | 2001-12-18 | American Home Products Corporation | Water soluble SDZ RAD esters |
| US6277983B1 (en) | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
| US6670355B2 (en) | 2000-06-16 | 2003-12-30 | Wyeth | Method of treating cardiovascular disease |
| DK1318837T3 (da) | 2000-08-11 | 2005-01-10 | Wyeth Corp | Fremgangsmåde til behandling af östrogenreceptorpositivt carcinom |
| DK1319008T3 (da) | 2000-09-19 | 2009-02-09 | Wyeth Corp | Vandoplöselige rapamycinestere |
| US6399625B1 (en) | 2000-09-27 | 2002-06-04 | Wyeth | 1-oxorapamycins |
| US6399626B1 (en) | 2000-10-02 | 2002-06-04 | Wyeth | Hydroxyesters of 7-desmethylrapamycin |
| US6440991B1 (en) | 2000-10-02 | 2002-08-27 | Wyeth | Ethers of 7-desmethlrapamycin |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| NZ537829A (en) | 2002-07-30 | 2006-09-29 | Wyeth Corp | Parenteral formulations containing a rapamycin hydroxyester |
| AU2003293529A1 (en) | 2002-12-16 | 2004-07-29 | Nitromed, Inc. | Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use |
| US7160867B2 (en) * | 2003-05-16 | 2007-01-09 | Isotechnika, Inc. | Rapamycin carbohydrate derivatives |
| ES2313328T3 (es) * | 2004-04-14 | 2009-03-01 | Wyeth | Procedimiento para la preparacion de 42-esteres de rapamicina y 32-esteres de fk-506 con acido dicarboxilico, precursores para conjugados de rapamicina y anticuerpos. |
| US20050239178A1 (en) * | 2004-04-27 | 2005-10-27 | Wyeth | Labeling of rapamycin using rapamycin-specific methylases |
| US20110104186A1 (en) | 2004-06-24 | 2011-05-05 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
| JP2008518966A (ja) * | 2004-10-28 | 2008-06-05 | ワイス | 子宮平滑筋腫の治療におけるｍＴＯＲ阻害剤の使用 |
| WO2006089207A2 (en) * | 2005-02-18 | 2006-08-24 | Abraxis Bioscience, Inc. | Drugs with improved hydrophobicity for incorporation in medical devices |
| GB0503936D0 (en) * | 2005-02-25 | 2005-04-06 | San Raffaele Centro Fond | Method |
| PT1912675E (pt) | 2005-07-25 | 2014-05-09 | Emergent Product Dev Seattle | Moléculas de ligaçao especificas para cd37 e especificas para cd20 |
| CN103110948A (zh) | 2005-11-04 | 2013-05-22 | 惠氏公司 | mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合 |
| US20080051691A1 (en) * | 2006-08-28 | 2008-02-28 | Wyeth | Implantable shunt or catheter enabling gradual delivery of therapeutic agents |
| US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
| US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US20080175887A1 (en) | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
| US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8430055B2 (en) | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
| US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| TW200901989A (en) | 2007-04-10 | 2009-01-16 | Wyeth Corp | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
| US20100048912A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| WO2009117669A2 (en) | 2008-03-21 | 2009-09-24 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
| CN102099377A (zh) | 2008-04-11 | 2011-06-15 | 新兴产品开发西雅图有限公司 | Cd37免疫治疗剂及其与双功能化学治疗剂的联合 |
| DK2365802T3 (da) | 2008-11-11 | 2017-11-13 | Univ Texas | Mikrokapsler af rapamycin og anvendelse til behandling af cancer |
| ES2552087T3 (es) | 2009-02-05 | 2015-11-25 | Tokai Pharmaceuticals, Inc. | Nuevos profármacos de inhibidores de CYP17 esteroidales/antiandrógenos |
| JP2013509444A (ja) | 2009-10-30 | 2013-03-14 | アリアド・ファーマシューティカルズ・インコーポレイテッド | がんの治療方法及び治療用組成物 |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| WO2015161139A1 (en) | 2014-04-16 | 2015-10-22 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| EP2542670A2 (en) | 2010-03-05 | 2013-01-09 | President and Fellows of Harvard College | Induced dendritic cell compositions and uses thereof |
| CA2795544A1 (en) | 2010-04-27 | 2011-11-03 | Roche Glycart Ag | Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor |
| WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
| US20150290176A1 (en) | 2012-10-12 | 2015-10-15 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors to treat vascular cognitive impairment |
| US20150258127A1 (en) | 2012-10-31 | 2015-09-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
| EP2968281B1 (en) | 2013-03-13 | 2020-08-05 | The Board of Regents of The University of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
| BR112015023098A2 (pt) | 2013-03-14 | 2017-07-18 | Univ Jefferson | agentes de infrarregulação do receptor de andrógeno e usos dos mesmos |
| CN105636594A (zh) | 2013-08-12 | 2016-06-01 | 托凯药业股份有限公司 | 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物 |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| AU2014373683B2 (en) | 2013-12-31 | 2020-05-07 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
| US10300070B2 (en) | 2014-03-27 | 2019-05-28 | The Brigham And Women's Hospital, Inc. | Metabolically-activated drug conjugates to overcome resistance in cancer therapy |
| KR20170031668A (ko) | 2014-06-02 | 2017-03-21 | 칠드런'즈 메디컬 센터 코포레이션 | 면역 조절을 위한 방법 및 조성물 |
| CN107073066B (zh) | 2014-09-11 | 2021-09-17 | 加利福尼亚大学董事会 | mTORC1抑制剂 |
| AU2016278040B2 (en) * | 2015-06-16 | 2019-07-04 | Nanophagix LLC | Drug delivery and imaging chemical conjugate, formulations and methods of use thereof |
| WO2017029391A1 (en) | 2015-08-20 | 2017-02-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method for treating cancer |
| ES2871499T3 (es) | 2017-05-15 | 2021-10-29 | Bard Inc C R | Dispositivo médico con recubrimiento de elución de fármaco y capa intermedia |
| EP3644997A1 (en) | 2017-06-26 | 2020-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of olmsted syndrome |
| JP2020527044A (ja) | 2017-07-13 | 2020-09-03 | アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） | ＣＤ８＋ＣＤ４５ＲＣＬＯＷ／−Ｔｒｅｇ集団の拡大増殖および免疫抑制能力を高めるための方法 |
| IL278335B2 (en) | 2018-05-01 | 2024-09-01 | Revolution Medicines Inc | C26-linked rapamycin analogs as mtor inhibitors |
| PL3788049T3 (pl) | 2018-05-01 | 2023-06-19 | Revolution Medicines, Inc. | Połączone z C40, C28 i C32 analogi rapamycyny jako inhibitory mTOR |
| WO2020023417A1 (en) | 2018-07-23 | 2020-01-30 | Enclear Therapies, Inc. | Methods of treating neurological disorders |
| CA3107352A1 (en) | 2018-07-23 | 2020-01-30 | Enclear Therapies, Inc. | Methods of treating neurological disorders |
| EP3849545A1 (en) | 2018-09-10 | 2021-07-21 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of neurofibromatosis |
| US11541152B2 (en) | 2018-11-14 | 2023-01-03 | Lutonix, Inc. | Medical device with drug-eluting coating on modified device surface |
| JP7487228B2 (ja) | 2019-04-08 | 2024-05-20 | バード・ペリフェラル・バスキュラー・インコーポレーテッド | 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス |
| AU2020271894A1 (en) | 2019-04-11 | 2021-12-02 | Enclear Therapies, Inc. | Methods of amelioration of cerebrospinal fluid and devices and systems therefor |
| IL301751A (en) | 2020-09-29 | 2023-05-01 | Enclear Therapies Inc | Subarachnoid fluid management method and system |
| WO2023288046A1 (en) | 2021-07-15 | 2023-01-19 | President And Fellows Of Harvard College | Compositions and methods relating to cells with adhered particles |
| JP2025522296A (ja) | 2022-05-25 | 2025-07-15 | レヴォリューション・メディスンズ，インコーポレイテッド | ｍＴＯＲ阻害剤によりがんを処置する方法 |
| CN115160343B (zh) * | 2022-06-09 | 2023-11-14 | 福建省微生物研究所 | 一种雷帕霉素衍生物及其制备方法和应用 |
| EP4551219A1 (en) | 2022-07-06 | 2025-05-14 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of proliferative glomerulonephritis |
| EP4565217A1 (en) | 2022-08-04 | 2025-06-11 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of lymphoproliferative disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) * | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US3993749A (en) * | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
| US4885171A (en) * | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
| US4316885A (en) * | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
| US4401653A (en) * | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
| US4650803A (en) * | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
| US5100899A (en) * | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
| WO1991013899A1 (en) * | 1990-03-12 | 1991-09-19 | Fujisawa Pharmaceutical Co., Ltd. | Tricyclo compounds |
| PT98990A (pt) * | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
| US5080899A (en) * | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
| US5078999A (en) * | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
| US5118678A (en) * | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5091389A (en) * | 1991-04-23 | 1992-02-25 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
| US5118677A (en) * | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
-
1992
- 1992-10-29 US US07/968,115 patent/US5262423A/en not_active Expired - Lifetime
-
1993
- 1993-08-21 TW TW082106771A patent/TW239136B/zh active
- 1993-10-06 JP JP6511079A patent/JPH08502748A/ja not_active Ceased
- 1993-10-06 AT AT93923284T patent/ATE166653T1/de not_active IP Right Cessation
- 1993-10-06 EP EP93923284A patent/EP0666861B1/en not_active Expired - Lifetime
- 1993-10-06 DE DE69318846T patent/DE69318846T2/de not_active Expired - Fee Related
- 1993-10-06 CA CA002148247A patent/CA2148247A1/en not_active Abandoned
- 1993-10-06 WO PCT/US1993/009552 patent/WO1994010176A1/en not_active Ceased
- 1993-10-06 DK DK93923284T patent/DK0666861T3/da active
- 1993-10-06 ES ES93923284T patent/ES2116471T3/es not_active Expired - Lifetime
- 1993-10-06 AU AU53222/94A patent/AU5322294A/en not_active Abandoned
- 1993-10-28 MX MX9306730A patent/MX9306730A/es not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1994010176A1 (en) | 1994-05-11 |
| EP0666861A1 (en) | 1995-08-16 |
| TW239136B (da) | 1995-01-21 |
| CA2148247A1 (en) | 1994-05-11 |
| JPH08502748A (ja) | 1996-03-26 |
| DE69318846T2 (de) | 1999-01-28 |
| US5262423A (en) | 1993-11-16 |
| DE69318846D1 (en) | 1998-07-02 |
| EP0666861B1 (en) | 1998-05-27 |
| ES2116471T3 (es) | 1998-07-16 |
| ATE166653T1 (de) | 1998-06-15 |
| AU5322294A (en) | 1994-05-24 |
| MX9306730A (es) | 1994-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0666861T3 (da) | Rapamycin-arylcarbonyl- og alkoxycarbonyl-carbamater som immunsuppressive og antifungiske midler | |
| WO2005092858A3 (en) | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist | |
| DK0612321T3 (da) | Pyridopyridazinon- og pyridazinthionforbindelser med PDE IV inhiberende aktivitet | |
| MX2024010096A (es) | Compuesto farmaceutico. | |
| DK0552031T3 (da) | Oxepan-isomere af rapamycin, der er anvendelige som immunsuppressive midler | |
| WO2002000650A3 (en) | Novel compounds possessing antibacterial, antifungal or antitumor activity | |
| AR027464A1 (es) | Oxamidas que son inhibidores de la inosina monofosfato deshidrogenasa (impdh) | |
| AU2910600A (en) | Phenyl urea and phenyl thiourea derivatives | |
| MXPA03009680A (es) | Derivados de amidopiperazina heterociclica de indol, azaindol y relacionados. | |
| TW200738706A (en) | Pyrido-, pyrazo-and pyrimido-pyrimidine derivatives and their use as mTOR inhibitors | |
| MY131013A (en) | Aryl derivatives | |
| CO5601011A2 (es) | Derivados de 3-ciclil-5-(anillo de 5 miembros que contiene nitrogeno) metil-oxazolidinona y su uso como agentes antibacterianos | |
| IL132474A (en) | 3,4-dihydrothienopyrimidine-4-(thi) ones for combating plant fungi and a novel such compound | |
| ES2177583T3 (es) | Nuevo compuesto tetraciclico. | |
| RU2008127257A (ru) | Тризамещенные производные хиназолинона в качестве ваниллоидных антагонистов | |
| PE20060455A1 (es) | Nucleosidos de 3-beta-d-ribofuranosiltiazolo[4,5-d]pirimidina | |
| DK1468692T3 (da) | Anvendelse af 2,6-di-alkyl-4-silyl-phenoler til behandling af xantom | |
| NO944069L (no) | Hemming av uterinfibrose | |
| TR200001941T1 (tr) | TNF ve PDE-IV önleyici aktiviteye sahip heterosiklik bileşiklerin N-oksitleri. | |
| ATE303398T1 (de) | Selektive glucocorticoid rezeptor agonisten | |
| DE60031699D1 (de) | Hydroxyacetamidobenzolsulfonamidderivate | |
| ATE101125T1 (de) | Phenylacetonitrilalkylaminoalkyl-(orthosubstituierte)-arylverbindungen als immunosupressoren. | |
| ATE271052T1 (de) | Wasserlösliche sdz-rad ester | |
| HUP9900601A2 (hu) | Benzopirán-származékok allograftkilökődés megelőzésére | |
| DE60028563D1 (de) | Aryl-chloralkyl harnstoffe |